Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial

There is no available effective systemic treatment for patients with advanced hepatocellular carcinoma (HCC) who are intolerant of sorafenib or who have disease that has progressed on sorafenib. In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitum...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Hepat Oncol
मुख्य लेखकों: Rimassa, Lorenza, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Finn, Richard S, Raoul, Jean-Luc, Schwartz, Lawrence H, He, Aiwu Ruth, Trojan, Joerg, Peck-Radosavljevic, Markus, Abbadessa, Giovanni, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Future Medicine Ltd 2014
विषय:
Clinical Trial Protocol
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095177/
https://ncbi.nlm.nih.gov/pubmed/30190953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन